A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-09-09
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-02-13 (study day 150); relationship: N
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-05-27 (study day 253); relationship: N
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-07-24 (study day 311); relationship: not assessed
Data queries
No data queries.